Adreview OverviewIobenguane I 131, marketed under the trade name Azedra, has had a clinical trial as a treatment for malignant, recurrent or unresectable pheochromocytoma and paraganglioma, and the FDA approved it on July 30, 2018. The drug is developed by Progenics Pharmaceuticals. References ^ Scarsbrook AF, Ganeshan A, Statham J, et al. (2007). "Anatomic and functional imaging of metastatic carcinoid tumors". Radiographics. 27 (2): 455–77. doi:10.1148/rg....
Read more Adreview Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Iobenguane
Recent Adreview Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Iobenguane I 123
- Injection: 555mbq/ml(15mci/ml), 5ml
- Solution: 10mci/5ml (2mci/ml), 15mci/ml
NDC Database Records for Adreview: (1 result)Sorted by National Drug Code
- 17156-235 Adreview 2 mci/Ml Intravenous Injection by Medi-physics Inc.